Further Responses in azer-cel Phase 1b Trial

Summary by 6ix AI

The trial continues to show promising results across multiple B-cell malignancies, with patient enrollment ongoing at various sites in the U.S. and Australia. These findings contribute to the growing clinical evidence supporting azer-cel's effectiveness in treating patients with significant unmet medical needs.

Written by 6ix AI from the company’s filing. How 6ix writes summaries